Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
WHO issues recommendations on management of isoniazid-resistant tuberculosis

Within the context of an ongoing extensive review of evidence on treatment of drug-resistant (TB) taking place in 2018, the World Health Organization (WHO) has issued a Supplement to its current drug-resistant TB treatment guidelines, providing recommendations for the management of isoniazid-resistant TB. These will be incorporated into the Consolidated Guidelines for Treatment and Care of Drug-resistant TB envisaged by WHO later in 2018.

Published
22 March 2018
From
World Health Organization
J&J, Macleods in talks for licence deal of tuberculosis drug

Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson(J&J) are in talks for a voluntary licence deal for the tuberculosis drug Bedaquiline, EThas learnt.

Published
13 March 2018
From
Economic Times
How both sides in Ukraine's war are losing the HIV battle

Displacement, aid delivery issues, and different strategies are all feeding a raging epidemic.

Published
16 February 2018
From
IRINnews.org
Promising MSF Research Highlights Immense Benefits, Need for Expanded Use of DR-TB Drug Combination

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of these medicines in combination for DR-TB patients worldwide.

Published
14 February 2018
From
MSF press release
TB treatment outcomes good for multidrug-resistant TB/HIV co-infected patients who start ART

Treatment of multidrug-resistant tuberculosis (TB) has comparable efficacy and survival rates in patients infected with HIV and not uninfected with HIV when patients with HIV are given antiretroviral therapy.

Published
01 February 2018
From
Medical Brief
A global study reveals new TB mutations that could transform tests for drug resistance

Resistance to the antibiotics used to treat TB is caused by mutations in the bacterial genome and new rapid molecular (DNA) tests are being developed, but detecting resistance relies on knowing which mutations to look for…. and there are potentially hundreds of mutations.

Published
24 January 2018
From
London School of Hygiene and Tropical Medicine
People still being denied improved treatment for multidrug-resistant TB

People with multidrug-resistant tuberculosis (MDR-TB) are still not receiving two newer TB drugs, bedaquiline and delamanid, which have been available for more than four years and have shown improved cure rates for the disease, deplored Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.

Published
16 October 2017
From
Médecins Sans Frontières (MSF) International
STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant tuberculosis

Preliminary results - released today at the 48th Union Conference on Lung Health - from Stage 1 of the STREAM randomised clinical trial show that the nine-month treatment regimen being tested achieved favourable outcomes in almost 80 percent of those treated. The results suggest the nine-month regimen is very close to the effectiveness of the 20-24 month regimen recommended in the 2011 WHO guidelines, when both regimens are given under trial conditions.

Published
16 October 2017
From
48th Union World Conference on Lung Health
In Early Results, Shorter Treatment for Tuberculosis Proves Effective

Taking the right antibiotics for just nine months may be as effective against drug-resistant tuberculosis as taking them for two years, as is currently recommended, according to preliminary findings from an international study.

Published
16 October 2017
From
New York Times
TB Alliance Moves Two Novel Tuberculosis Drugs into Human Trials

TBA-7371 and Sutezolid Help Fill Sparse Pipeline of New Antibiotics Against a Disease That Grows Increasingly Resistant to Older Drugs.

Published
11 October 2017
From
TB Alliance

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.